"I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, ...

Q4 2025 Management View CEO Robert Ford highlighted that 2025 showcased "Abbott's leadership in innovation, disciplined execution and strategic actions taken to position the company for sustainable ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was extreme. "I ...